1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Nosocomial Infections Global Clinical Trials Review, H2, 2014

Nosocomial Infections Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Nosocomial Infections Global Clinical Trials Review, H2, 2014" provides data on the Nosocomial Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nosocomial Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nosocomial Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Nosocomial Infections Global Clinical Trials Review, H2, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Nosocomial Infections 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Nosocomial Infections to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Nosocomial Infections to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Nosocomial Infections 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Nosocomial Infections Therapeutics Clinical Trials 30
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
Pfizer Inc. 32
Clinical Trial Overview of Pfizer Inc. 32
AstraZeneca PLC 34
Clinical Trial Overview of AstraZeneca PLC 34
Merck and Co., Inc. 35
Clinical Trial Overview of Merck and Co., Inc. 35
Bayer AG 36
Clinical Trial Overview of Bayer AG 36
Tetraphase Pharmaceuticals Inc. 37
Clinical Trial Overview of Tetraphase Pharmaceuticals Inc. 37
Janssen Pharmaceuticals, Inc. 38
Clinical Trial Overview of Janssen Pharmaceuticals, Inc. 38
Johnson and Johnson 39
Clinical Trial Overview of Johnson and Johnson 39
Cubist Pharmaceuticals, Inc. 40
Clinical Trial Overview of Cubist Pharmaceuticals, Inc. 40
Janssen Research and Development, LLC 41
Clinical Trial Overview of Janssen Research and Development, LLC 41
Achaogen Inc. 42
Clinical Trial Overview of Achaogen Inc. 42
Clinical Trial Overview of Top Institutes / Government 43
University of Oxford 43
Clinical Trial Overview of University of Oxford 43
Mashhad University of Medical Sciences 44
Clinical Trial Overview of Mashhad University of Medical Sciences 44
Department of Health, UK 45
Clinical Trial Overview of Department of Health, UK 45
Medical University of Warsaw 46
Clinical Trial Overview of Medical University of Warsaw 46
Rigshospitalet 47
Clinical Trial Overview of Rigshospitalet 47
Hopitaux Universitaires de Geneve 48
Clinical Trial Overview of Hopitaux Universitaires de Geneve 48
University of Calgary 49
Clinical Trial Overview of University of Calgary 49
U.S. Department of Veterans Affairs 50
Clinical Trial Overview of U.S. Department of Veterans Affairs 50
Duke University 51
Clinical Trial Overview of Duke University 51
University of Cincinnati 52
Clinical Trial Overview of University of Cincinnati 52
Five Key Clinical Profiles 53
Appendix 101
Abbreviations 101
Definitions 101
Research Methodology 102
Secondary Research 102
About GlobalData 103
Contact Us 103
Disclaimer 103
Source 103

List of Tables
Nosocomial Infections Therapeutics, Global, Clinical Trials by Region, 2014* 7
Nosocomial Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Nosocomial Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Nosocomial Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Nosocomial Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Nosocomial Infections Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Nosocomial Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Nosocomial Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Nosocomial Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Nosocomial Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Nosocomial Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Nosocomial Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Nosocomial Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Nosocomial Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Nosocomial Infections Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Nosocomial Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Nosocomial Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Nosocomial Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Nosocomial Infections Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Nosocomial Infections Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Nosocomial Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Nosocomial Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Nosocomial Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Nosocomial Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Nosocomial Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 32
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 34
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 35
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 36
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Tetraphase Pharmaceuticals Inc., 2014* 37
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Pharmaceuticals, Inc., 2014* 38
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 39
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Cubist Pharmaceuticals, Inc., 2014* 40
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Research and Development, LLC, 2014* 41
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Achaogen Inc., 2014* 42
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2014* 43
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Mashhad University of Medical Sciences, 2014* 44
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Department of Health, UK, 2014* 45
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Warsaw, 2014* 46
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Rigshospitalet, 2014* 47
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Hopitaux Universitaires de Geneve, 2014* 48
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Calgary, 2014* 49
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 50
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 51
Nosocomial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Cincinnati, 2014* 52

List of Figures
Nosocomial Infections Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Nosocomial Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Nosocomial Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Nosocomial Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Nosocomial Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Nosocomial Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Nosocomial Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Nosocomial Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Nosocomial Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Nosocomial Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Nosocomial Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Nosocomial Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Nosocomial Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Nosocomial Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Nosocomial Infections Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Nosocomial Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Nosocomial Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Nosocomial Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Nosocomial Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Nosocomial Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Nosocomial Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Nosocomial Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Nosocomial Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 102

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.